EQ Equillium, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%
Returns
ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $41.09M |
| R&D expense | $12.84M | $37.43M |
| SG&A expense | $10.79M | $11.94M |
| Operating income | -$23.63M | -$8.27M |
| Pretax income | -$22.40M | -$7.71M |
| Income tax | $0 | $361,000 |
| Net income | -$22.40M | -$8.07M |
| EBITDA | -$23.52M | -$8.13M |
| EPS (basic) | -0.39 | -0.23 |
| EPS (diluted) | -0.39 | -0.23 |
| Weighted avg. shares (diluted) | 57.30M | 35.36M |
| Balance sheet | ||
| Cash & equivalents | $30.28M | $18.09M |
| Short-term investments | — | $4.49M |
| Receivables | — | $0 |
| Current assets | $31.04M | $24.98M |
| PP&E, net | $164,000 | $262,000 |
| Total assets | $31.89M | $25.60M |
| Current liabilities | $2.93M | $6.36M |
| Total liabilities | $3.29M | $6.54M |
| Shareholders' equity | $28.60M | $19.06M |
| Shares outstanding | 61.46M | 35.56M |
| Cash flow statement | ||
| Operating cash flow | -$22.75M | -$19.03M |
| Capital expenditure | $48,000 | $85,000 |
| Free cash flow | -$22.79M | -$19.11M |
| Investing cash flow | $4.46M | $13.81M |
| Financing cash flow | $30.43M | $164,000 |
| Depreciation & amortization | $116,000 | $137,000 |
| Stock-based compensation | $2.32M | $3.75M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.